Organ transplant recipients with Merkel cell carcinoma have reduced progression-free, overall, and disease-specific survival independent of stage at presentation

Journal of the American Academy of Dermatology

Volumn 71, Issue 4, 2014, Pages 684-690

  Arron, Sarah T ^a   Canavan, Theresa ^a   Yu, Siegrid S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Merkel cell carcinoma; Organ transplant; Outcomes; Survival

Indexed keywords

AZATHIOPRINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN;

AGE; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HIGH RISK POPULATION; HUMAN; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MERKEL CELL TUMOR; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEX; SOLID ORGAN TRANSPLANT RECIPIENT; ANALYSIS OF VARIANCE; CASE CONTROL STUDY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MORTALITY; ORGAN TRANSPLANT; OUTCOMES; PATHOLOGY; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; REFERENCE VALUE; RISK ASSESSMENT; SKIN TUMOR; SURVIVAL; TREATMENT OUTCOME; TUMOR INVASION; UNIVERSITY HOSPITAL; VERY ELDERLY;

MERKEL CELL CARCINOMA; ORGAN TRANSPLANT; OUTCOMES; SURVIVAL;

ACADEMIC MEDICAL CENTERS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA, MERKEL CELL; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORGAN TRANSPLANTATION; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84910153786     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.05.054     Document Type: Article

References (38)

1. Kempf W, Mertz KD, Hofbauer GF, Tinguely M. Skin cancer in organ transplant recipients. Pathobiology 2013;80:302-9.
2. Albores-Saavedra J, Batich K, Chable-Montero F, Sagy N, Schwartz AM, Henson DE. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol 2010;37:20-7.
3. Penn I, First MR. Merkel's cell carcinoma in organ recipients: report of 41 cases. Transplantation 1999;68:1717-21.
4. Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol 2003; 49:832-41.
5. Buell JF, Trofe J, Hanaway MJ, Beebe TM, Gross TG, Alloway RR, et al. Immunosuppression and Merkel cell cancer. Transplant Proc 2002;34:1780-1.
6. Heath M, Jaimes N, Lemos B, Mostaghimi A, Wang LC, Penas PF, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol 2008;58:375-81.
7. Tadmor T, Liphshitz I, Aviv A, Landgren O, Barchana M, Polliack A. Increased incidence of chronic lymphocytic leukemia and lymphomas in patients with Merkel cell carcinomaea population based study of 335 cases with neuroendocrine skin tumor. Br J Haematol 2012;157:457-62.
8. Engels EA, Frisch M, Goedert JJ, Biggar RJ, Miller RW. Merkel cell carcinoma and HIV infection. Lancet 2002;359:497-8.
9. Paulson KG, Iyer JG, Blom A, Warton EM, Sokil M, Yelistratova L, et al. Systemic immune suppression predicts diminished Merkel cell carcinomaespecific survival independent of stage. J Invest Dermatol 2013;133:642-6.
10. Brewer JD, Shanafelt TD, Otley CC, Roenigk RK, Cerhan JR, Kay NE, et al. Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study. J Clin Oncol 2012;30:843-9.
11. Tarantola TI, Vallow LA, Halyard MY, Weenig RH, Warschaw KE, Grotz TE, et al. Prognostic factors in Merkel cell carcinoma: analysis of 240 cases. J Am Acad Dermatol 2013;68:425-32.
12. Zur Hausen H. The search for infectious causes of human cancers: where and why. Virology 2009;392:1-10.
13. Gandhi RK, Rosenberg AS, Somach SC. Merkel cell polyomavirus: an update. J Cutan Pathol 2009;36:1327-9.
14. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008; 319:1096-100.
15. Andres C, Belloni B, Puchta U, Sander CA, Flaig MJ. Prevalence of MCPyV in Merkel cell carcinoma and non-MCC tumors. J Cutan Pathol 2010;37:28-34.
16. Duncavage EJ, Zehnbauer BA, Pfeifer JD. Prevalence of Merkel cell polyomavirus in Merkel cell carcinoma. Mod Pathol 2009; 22:516-21.
17. Becker JC, Houben R, Ugurel S, Trefzer U, Pfohler C, Schrama D. MC polyomavirus is frequently present in Merkel cell carcinoma of European patients. J Invest Dermatol 2009;129: 248-50.
18. Wieland U, Kreuter A. Merkel cell polyomavirus infection and Merkel cell carcinoma in HIV-positive individuals. Curr Opin Oncol 2011;23:488-93.
19. Paulson KG, Iyer JG, Tegeder AR, Thibodeau R, Schelter J, Koba S, et al. Transcriptome-wide studies of Merkel cell carcinoma and validation of intratumoral CD81 lymphocyte invasion as an independent predictor of survival. J Clin Oncol 2011;29: 1539-46.
20. Sihto H, Bohling T, Kavola H, Koljonen V, Salmi M, Jalkanen S, et al. Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: a population-based study. Clin Cancer Res 2012;18:2872-81.
21. Kubica AW, Brewer JD. Melanoma in immunosuppressed patients. Mayo Clin Proc 2012;87:991-1003.
22. Brewer JD, Christenson LJ, Weaver AL, Dapprich DC, Weenig RH, Lim KK, et al. Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis. Arch Dermatol 2011;147:790-6.
23. Rodrigues LKE, Klencke BJ, Vin-Christian K, Berger TG, Crawford RI, Miller JR III, et al. Altered clinical course of malignant melanoma in HIV-positive patients. Arch Dermatol 2002;138: 765-70.
24. Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spooner K, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency viruseinfected individuals. Cancer 2005; 104:1505-11.
25. Koljonen V, Kukko H, Tukiainen E, Bohling T, Sankila R, Pukkala E, et al. Incidence of Merkel cell carcinoma in renal transplant recipients. Nephrol Dial Transplant 2009;24:3231-5.
26. Lanoy E, Engels EA. Skin cancers associated with autoimmune conditions among elderly adults. Br J Cancer 2010;103:112-4.
27. Hemminki K, Liu X, Ji J, Sundquist J, Sundquist K. Kaposi sarcoma and Merkel cell carcinoma after autoimmune disease. Int J Cancer 2012;131:E326-8.
28. Muirhead R, Ritchie DM. Partial regression of Merkel cell carcinoma in response to withdrawal of azathioprine in an immunosuppression-induced case of metastatic Merkel cell carcinoma. Clin Oncol (R Coll Radiol) 2007;19:96.
29. Burack J, Altschuler EL. Sustained remission of metastatic Merkel cell carcinoma with treatment of HIV infection. J R Soc Med 2003;96:238-9.
30. Bhatia S, Afanasiev O, Nghiem P. Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer. Curr Oncol Rep 2011;13: 488-97.
31. Goronzy JJ, Lee W-W, Weyand CM. Aging and T-cell diversity. Exp Gerontol 2007;42:400-6.
32. Teicher BA. Transforming growth factor-beta and the immune response to malignant disease. Clin Cancer Res 2007;13: 6247-51.
33. Houston A, Bennett MW, O'Sullivan GC, Shanahan F, O'Connell J. Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression. Br J Cancer 2003;89:1345-51.
34. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of ''tumor escape'' phenotypes. Nat Immunol 2002;3:999-1005.
35. Rubinstein N, Ilarregui JM, Toscano MA, Rabinovich GA. The role of galectins in the initiation, amplification and resolution of the inflammatory response. Tissue Antigens 2004;64:1-12.
36. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269-74.
37. Dowlatshahi M, Huang V, Gehad A, Jiang Y, Calarese A, Teague JE, et al. Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T cell exhaustion in reducing T cell responses. J Invest Dermatol 2013;133: 1879-89.
38. Ullrich SE. Mechanisms underlying UV-induced immune suppression. Mutat Res 2005;571:185-205.